Origin:
Inspired by a speech
by antiseptic advocate Joseph Lister, Robert Wood Johnson, joined brothers James Wood Johnson and Edward Mead Johnson to
create a line of ready-to-use surgical dressings in
1885. The company produced its first products in 1886 and incorporated in
1887.
Robert Wood Johnson
served as the first president of the company. He worked to improve sanitation practices in the nineteenth century, and lent his name
to a hospital in New Brunswick, New
Jersey.
Upon his death in 1910, he was succeeded in the presidency by his brother James
Wood Johnson until 1932, and then by his son, Robert Wood Johnson
II.
RWJ's
granddaughter, Mary Lea Johnson
Richards, was the first baby to appear on a Johnson & Johnson
baby powder label. His great-grandson, Jamie Johnson,
made a documentary called Born Rich about the experience of growing up as the heir to one
of the world's greatest fortunes.
History:
Johnson & Johnson (NYSE: JNJ) is an American multinational medical devices, pharmaceutical and
consumer packaged goods manufacturer founded in 1886. Its common stock is
a component of the Dow Jones Industrial Average and the company is listed among the Fortune 500.
Johnson & Johnson consistently ranks at the top of Harris Interactive's National Corporate Reputation
Survey, ranking as the world's
most respected company by Barron's Magazine, and was the first corporation awarded
the Benjamin Franklin Award for Public Diplomacy by the U.S. State Department
for its funding of international education programs. A suit brought by the United States Department of Justice in 2010, however,
alleges that, from 1999 to 2004, the company illegally marketed drugs including antipsychotics to Omnicare, a pharmacy that dispenses the drugs in nursing homes. Johnson & Johnson responded that
the payments were lawful and appropriate.
The corporation's headquarters is located in New Brunswick, New Jersey, United States with the consumer division being located in Skillman, New Jersey. The corporation includes some
250 subsidiary companies with operations in over 57 countries and products sold
in over 175 countries. Johnson & Johnson had worldwide pharmaceutical sales
of $65 billion for the calendar year of 2011.
Johnson & Johnson's brands include numerous household
names of medications and first
aid supplies. Among its well-known consumer products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson's
baby products, Neutrogena skin
and beauty products, Clean
& Clear facial wash and Acuvue contact
lenses.
In 2012, Johnson & Johnson announced that they will
start to fund the therapeutic device company Clarimedix Inc. to support "proof of concept"
study.
Milestones:
Caring for the world, one person at a
time... inspires and unites the people of Johnson & Johnson. They
embrace research and science - bringing innovative ideas, products and services
to advance the health and well-being of people. Employees of the
Johnson & Johnson Family of Companies work with partners in
health care to touch the lives of over a billion people every day, throughout the
world.
Their Family of Companies comprises:
·
The world’s
sixth-largest consumer health company.
·
The world’s
largest and most diverse medical devices and diagnostics company.
·
The world’s
fifth-largest biologics company.
·
And the world’s
eighth-largest pharmaceuticals company
They have more than 250 operating
companies in 60 countries employing approximately 129,000 people. Our worldwide
headquarters is in New Brunswick, New Jersey, USA.
2010 Renewable Energy Milestone: Janssen Turns On New
Jersey’s Largest Solar Energy System Sept. 23
Titusville, N.J. (Sept. 22, 2010) –
With the flip of a switch on Thursday, the largest solar panel array in
New Jersey will come to life on the campus of Janssen, Division of
Ortho-McNeil-Janssen Pharmaceuticals, Inc., as company leaders and employees
inaugurate the largest solar installation of any site among the Johnson &
Johnson Family of Companies around the world.
The 4.1 megawatt (MW) solar photovoltaic array of 13,496 ground-mounted panels tracks the sun from east to west, and is estimated to generate enough energy to provide 70 percent of the site’s annual electricity needs, or roughly the amount needed to power 600 homes annually. The Titusville site, which hosts multiple Johnson & Johnson companies, broke ground on the array in April.
In addition to the Titusville site, Johnson & Johnson has solar power systems planned or completed at 20 sites worldwide, which together represent an installed capacity of about 13 megawatts.
The Titusville campus is one of several Johnson & Johnson sites that are certified as Leadership in Energy & Environmental Design (LEED) sites. LEED is an internationally recognized green certification system aimed at improving performance across key metrics, such as energy savings, water efficiency, carbon dioxide emissions reduction, improved indoor environmental quality, stewardship of resources and sensitivity to their impacts.
The U.S. Environmental Protection Agency (EPA) Green Power Partnership lists the company as the nation’s sixth-largest purchaser of renewable energy. Johnson & Johnson also has received six Green Power Leadership Awards from the EPA and Department of Energy since 2002.
The 4.1 megawatt (MW) solar photovoltaic array of 13,496 ground-mounted panels tracks the sun from east to west, and is estimated to generate enough energy to provide 70 percent of the site’s annual electricity needs, or roughly the amount needed to power 600 homes annually. The Titusville site, which hosts multiple Johnson & Johnson companies, broke ground on the array in April.
In addition to the Titusville site, Johnson & Johnson has solar power systems planned or completed at 20 sites worldwide, which together represent an installed capacity of about 13 megawatts.
The Titusville campus is one of several Johnson & Johnson sites that are certified as Leadership in Energy & Environmental Design (LEED) sites. LEED is an internationally recognized green certification system aimed at improving performance across key metrics, such as energy savings, water efficiency, carbon dioxide emissions reduction, improved indoor environmental quality, stewardship of resources and sensitivity to their impacts.
The U.S. Environmental Protection Agency (EPA) Green Power Partnership lists the company as the nation’s sixth-largest purchaser of renewable energy. Johnson & Johnson also has received six Green Power Leadership Awards from the EPA and Department of Energy since 2002.
Mission
Statement:
J&J doesn't have a "mission
statement." Instead, they have a credo.
At Johnson & Johnson there is no mission statement that hangs on the wall. Instead, for more than 60 years, a simple, one-page document – Our Credo – has guided our actions in fulfilling our responsibilities to our customers, our employees, the community and our stockholders. Our worldwide Family of Companies shares this value system in 36 languages spreading across Africa, Asia/Pacific, Eastern Europe, Europe, Latin America, Middle East and North America. The English version of the Credo is below, or you may choose to view it in another language by selecting a country from the box on the right. You can also learn more about the history of Our Credo and its development.
At Johnson & Johnson there is no mission statement that hangs on the wall. Instead, for more than 60 years, a simple, one-page document – Our Credo – has guided our actions in fulfilling our responsibilities to our customers, our employees, the community and our stockholders. Our worldwide Family of Companies shares this value system in 36 languages spreading across Africa, Asia/Pacific, Eastern Europe, Europe, Latin America, Middle East and North America. The English version of the Credo is below, or you may choose to view it in another language by selecting a country from the box on the right. You can also learn more about the history of Our Credo and its development.
Our
Credo
We believe our first responsibility is to the doctors, nurses and patients,
to mothers and fathers and all others who use our products and services.
In meeting their needs everything we do must be of high quality.
We must constantly strive to reduce our costs
in order to maintain reasonable prices.
Customers' orders must be serviced promptly and accurately.
Our suppliers and distributors must have an opportunity
to make a fair profit.
We are responsible to our employees,
the men and women who work with us throughout the world.
Everyone must be considered as an individual.
We must respect their dignity and recognize their merit.
They must have a sense of security in their jobs.
Compensation must be fair and adequate,
and working conditions clean, orderly and safe.
We must be mindful of ways to help our employees fulfill
their family responsibilities.
Employees must feel free to make suggestions and complaints.
There must be equal opportunity for employment, development
and advancement for those qualified.
We must provide competent management,
and their actions must be just and ethical.
We are responsible to the communities in which we live and work
and to the world community as well.
We must be good citizens – support good works and charities
and bear our fair share of taxes.
We must encourage civic improvements and better health and education.
We must maintain in good order
the property we are privileged to use,
protecting the environment and natural resources.
Our final responsibility is to our stockholders.
Business must make a sound profit.
We must experiment with new ideas.
Research must be carried on, innovative programs developed
and mistakes paid for.
New equipment must be purchased, new facilities provided
and new products launched.
Reserves must be created to provide for adverse times.
When we operate according to these principles,
the stockholders should realize a fair return.
We believe our first responsibility is to the doctors, nurses and patients,
to mothers and fathers and all others who use our products and services.
In meeting their needs everything we do must be of high quality.
We must constantly strive to reduce our costs
in order to maintain reasonable prices.
Customers' orders must be serviced promptly and accurately.
Our suppliers and distributors must have an opportunity
to make a fair profit.
We are responsible to our employees,
the men and women who work with us throughout the world.
Everyone must be considered as an individual.
We must respect their dignity and recognize their merit.
They must have a sense of security in their jobs.
Compensation must be fair and adequate,
and working conditions clean, orderly and safe.
We must be mindful of ways to help our employees fulfill
their family responsibilities.
Employees must feel free to make suggestions and complaints.
There must be equal opportunity for employment, development
and advancement for those qualified.
We must provide competent management,
and their actions must be just and ethical.
We are responsible to the communities in which we live and work
and to the world community as well.
We must be good citizens – support good works and charities
and bear our fair share of taxes.
We must encourage civic improvements and better health and education.
We must maintain in good order
the property we are privileged to use,
protecting the environment and natural resources.
Our final responsibility is to our stockholders.
Business must make a sound profit.
We must experiment with new ideas.
Research must be carried on, innovative programs developed
and mistakes paid for.
New equipment must be purchased, new facilities provided
and new products launched.
Reserves must be created to provide for adverse times.
When we operate according to these principles,
the stockholders should realize a fair return.
Awards
& Recognition:
Johnson &
Johnson is proud to be recognized by important organizations
and publications for the many ways we have embraced diversity as a part of the
cultures of our Family of Companies. This recognition includes:
Johnson & Johnson was named
to Fortune magazine’s list of the World’s Most Admired
Companies in 2012.
Johnson & Johnson was named one of
the 10 Best U.S. Corporations for Veteran-Owned Businesses for 2012 by the
National Veteran-Owned Business Association (NaVOBA).
Johnson & Johnson received a
perfect score of 100% for the seventh consecutive year on the annual Corporate
Equality Index (CEI) by the Human Rights Campaign Foundation (HRC) in 2011.
The United Nations awarded
Johnson & Johnson the 2011 Humanitarian of the Year Award for our
leading role in its Healthy Mother, Healthy Child initiative.
Johnson & Johnson
continues to be a member company of the FTSE4Good Index, the responsible
investment index calculated by global index provider FTSE Group.
Working Mother magazine has named
Johnson & Johnson one of the “Top 100 Companies for Working
Mothers” every year since the list was initiated 26 years ago.
Leaders throughout the Johnson & Johnson
Family of Companies have also been recognized through the years for their
contributions and initiative in the area of diversity and inclusion.
Awards
won in 2012:
1.
Forbes:
a.
Johnson & Johnson ranked No. 9 among the top 20
companies in Forbes 7th annual
2.
“Best Companies for Leadership” survey:
a.
American College of Occupational and Environmental
Medicine Johnson & Johnson received the 2012 Corporate Health Achievement
Award from the American College of Occupational and Environmental Medicine in
recognition of its long history of commitment to the safety and health of its
workers.
3.
Diversity Inc Magazine:
a.
Johnson & Johnson was ranked No. 11 by Diversity Inc magazine on its “2012
Diversity Inc Top 50 Companies
for Diversity®” list.
4.
The Reputation Institute:
a.
Johnson & Johnson ranked No. 3 on this year’s
Forbes/Reputation Institute survey. This is the seventh consecutive year that
the company appeared in the top 10.
5.
World at Work’s Alliance for Work-Life Progress
(AWLP):
a.
Johnson & Johnson was awarded a Work-Life Seal
of Distinction to recognize organizations that exemplify leadership in
work-life effectiveness.
6.
Vetrepreneur Magazine:
a.
Johnson & Johnson was named one of the 10 Best
U.S. Corporations for Veteran-Owned Businesses for 2012 by the National Veteran-Owned
Business Association (NaVOBA).
7.
FORTUNE Magazine:
a.
Johnson & Johnson was named to FORTUNE magazine’s list of
the World’s Most Admired Companies in 2012. National Association for Female
Executives Award: Johnson & Johnson was listed in the Top 10 of the 50 Top
Companies for Women Executives.
Products
& Services:
§ Desitin
§ Johnson & Johnson
Red Cross
§ Meds
§ Micralax
§ Neko
§ O.B.
§ RoC
§ Ultracet
Founded
in 1886 in New Brunswick, New Jersey, USA, Johnson & Johnson spread its
roots into India in 1947 with the arrival of Mr. Patrick Whaley and in 1948,
started marketing Johnson’s Baby Powder which was manufactured by a local
company, British Drug House, in Mumbai. In September 1957, a new company -
Johnson & Johnson Limited was created and registered with 12 employees on
its roll. The company was licensed to manufacture a broad range of consumer and
hospital products. Production began in 1959 from the earliest Johnson &
Johnson plant in Mulund in Mumbai.
Mr. Whaley
became the first MD of the company and served for 14 years. The company
prospered under his able leadership. In the years that followed, Johnson &
Johnson Limited established a reputation for quality with a range of products
that represented virtually every sector of the company’s business
internationally.
The
60s was a decade of manufacturing growth. The first Ethicon plant was set up in
Dharavi in Mumbai to manufacture Catgut sutures. In 1966, the Bhandup plant in
Mumbai was set up to manufacture feminine hygiene products. The Ortho
Diagnostics’ manufacturing unit was set up in 1970 and shifted to Deonar in
Mumbai. In 1975, Ethnor Limited (merged with Johnson & Johnson in 1994) set
up a plant for manufacturing pharmaceutical and ethical products of Ortho-McNeil
Laboratories and Cilag Chemie. A second manufacturing plant for personal
products started in Bhandup in Mumbai. The state-of-the-art Ethicon plant in
Aurangabad became operational in 1991. The latest addition to the family is the
manufacturing facilities in Baddi in Himachal Pradesh, which caters to both
medical and consumer sectors. Currently, the manufacturing plants are at Baddi
(2), Mulund, Aurangabad, Deonar and offices at Mumbai (4), Chennai, Delhi,
Kolkata, a pharma R&D Center in Mulund, a Global Clinical Operations (GCO)
office in Powai, Mumbai, and a Business Knowledge Center in Pune &
Bengaluru.
In
over 50 years of operating in India, Johnson & Johnson Limited has gained a
reputation for delivering high-quality products.
Man
Power & Organizational Structure:
Johnson & Johnson has more than 250 companies located in
57 countries around the world. Our Family of Companies is organized into
several business segments comprised of franchises and therapeutic categories.
The Consumer segment includes a broad range of products used in the baby
care, skin care, oral care, wound care and women’s health care fields, as well
as nutritional and over-the-counter pharmaceutical products, and wellness and
prevention platforms.
The Medical Devices and Diagnostics segment produces a broad range of
innovative products used primarily by health care professionals in the fields
of orthopaedics, neurovascular, surgery, vision care, diabetes care, infection
prevention, diagnostics, cardiovascular disease, sports medicine, and
aesthetics.
The Pharmaceutical segment’s broad portfolio focuses on unmet medical
needs across several therapeutic areas: cardiovascular & metabolism,
immunology, infectious diseases & vaccines, neuroscience & pain, and
oncology.
Today,
they employ more than 2000 people and the businesses span Consumer, Medical
Devices & Diagnostics, Pharmaceuticals and Vision Care.
Financial
Performance:
NEW BRUNSWICK, N.J., April 17, 2012 /PRNewswire-FirstCall/ -- Johnson
& Johnson (NYSE: JNJ) today announced sales of $16.1 billion for the first quarter of 2012, a
decrease of 0.2% as compared to the first quarter of 2011. Operational
results increased 1.0% and the negative impact of currency was 1.2%.
Domestic sales declined 5.1%. International sales increased 4.1%,
reflecting operational growth of 6.4% and a negative currency impact of 2.3%.Net earnings and diluted earnings per share for the first quarter of 2012 were $3.9 billion and $1.41, respectively. First quarter 2012 net earnings included an after-tax gain of $106 million primarily related to the currency adjustment associated with the planned acquisition of Synthes, Inc. First quarter 2011 net earnings included after-tax charges of $271 million representing expenses due to litigation and DePuy ASR™ Hip recall costs. Excluding these special items, net earnings for the current quarter were $3.8 billion and diluted earnings per share were $1.37, representing increases of 1.5% and 1.5%, respectively, as compared to the same period in 2011.*
The Company updated its earnings guidance for full-year 2012 to $5.07 - $5.17 per share to reflect the positive impact of current exchange rates. The Company's guidance excludes the impact of special items.
Worldwide Consumer sales of $3.6 billion for the first quarter represented a decrease of 2.4% versus the prior year consisting of an operational decline of 0.6% and a negative impact from currency of 1.8%. Domestic sales decreased 2.2%. International sales decreased 2.5%, which reflected an operational increase of 0.4% and a negative currency impact of 2.9%.
Sales of the U.S. over-the-counter medicines were significantly impacted by the suspension of manufacturing at the McNeil Consumer Healthcare facility in Fort Washington, Pa., and the impact on production volumes related to ongoing efforts to enhance quality and manufacturing systems. Positive contributors to operational results were NEUTROGENA® skin care products and international sales of oral care products.
Worldwide Pharmaceutical sales of $6.1 billion for the first quarter represented an increase of 1.2% versus the prior year with operational growth of 2.6% and a negative impact from currency of 1.4%. Domestic sales decreased 10.8%. International sales increased 16.5% which reflected an operational increase of 19.6% and a negative currency impact of 3.1%.
Positive contributors to international sales were strong results for REMICADE® (infliximab), a biologic approved for the treatment of a number of immune-mediated, inflammatory diseases, representing incremental sales from international territories included in the amended distribution agreement with Merck; VELCADE® (bortezomib), a treatment for multiple myeloma; and sales of recently launched products.
The strong sales results of recently launched products, include ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone or prednisolone, for the treatment of men with metastatic, castration-resistant prostate cancer; STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; and international sales of INCIVO® (telaprevir), a direct acting antiviral protease inhibitor, for the treatment of genotype-1 chronic hepatitis C virus, in combination with peginterferon alfa and ribavirin, in adults.
Future
Plans:
J&J Corporation has a very good perception of India. This has
been supported by good results in the country. The outlook is bullish, and is
supported by a high level of confidence in the Indian management team and more
investments likely in the coming years. Double-digit growth is forecast for the
India operations. India would be a key growth driver for J&J worldwide. J&J
is also exploring the opportunities for setting up BPO operations in the
country.
Corporate
Social Responsibility:
Johnson & Johnson and its many operating companies
support community-based programs that improve health and well-being. Our
community partners show us where our giving can help the most. We listen to
them and we learn from them so that the programs we support make a meaningful difference
in people’s lives. Together
with our partners, we are helping mothers and infants survive childbirth. We
are supporting doctors, nurses and local leaders as they work to provide the
best medical care to their people. And we are educating communities on how to
reduce their risk of infection from preventable diseases. The desire to make people healthier and safer is at the
heart of our Company’s giving.
An initiative dedicated to helping
improve women and children’s health in
the developing world.
|
This is a comprehensive online
resource and community developed to help family caregivers care for their
loved ones and themselves.
|
|
Safe Kids Worldwide is a global
network of organizations with a mission of preventing unintentional childhood
injury, a leading cause of death and disability for children ages 14 and
under.
|
|
\
|
This advertising campaign, which ran
in China, celebrates the unsung heroes who dedicate themselves to caring for
others.
|
This campaign uses real moms and dads
in real situations to celebrate the joys of parenthood.
|
